SELLAS Life Sciences Group Inc (NAS:SLS)
$ 0.98 -0.03 (-2.97%) Market Cap: 68.97 Mil Enterprise Value: 50.63 Mil PE Ratio: 0 PB Ratio: 3.92 GF Score: 39/100

Sellas Life Sciences Group Inc Galinpepimut-S Update Call Transcript

Nov 14, 2022 / 01:30PM GMT
Release Date Price: $2.55 (-43.96%)
Operator

Hello, and thank you for standing by. Welcome to the SELLAS Life Science [REGAL] Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to introduce your host, Allison Soss, Investor Relations. Please go ahead.

Allison Soss
Kanan, Corbin, Schupak & Aronow, Inc. - SVP of IR

Good morning, everyone. The focus of today's call is SELLAS's Phase III clinical trial of GPS in patients with acute myeloid leukemia and second remission, the REGAL study.

Dr. Angelos Stergiou, the company's President and Chief Executive Officer, will begin today's call with some important updates regarding the REGAL, [according] REGAL; and then introduce our additional speaker, Dr. Yair Levy of Baylor University Medical Center; as well as Dr. Dragan Cicic, SELLASâs SVP of Clinical Development, who will participate in the Q&A.

Following the presentations, we will hold a Q&A session as we will likely not have time to answer every question, we will give priority to questions from the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot